Antheia is unlocking the medicinal power of nature with synthetic biology. Through a novel whole-cell engineering approach to reconstruct complex molecules in yeast, Antheia's platform enables the discovery and manufacturing of plant-inspired drugs of unprecedented complexity and diversity.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/30/21 | $73,000,000 | Series B |
Hillspire Sherpalo Viking Global Investors  | undisclosed |
| 07/19/24 | $17,000,000 |
BioMaP Consortium Echo Investment Capital In-Q-Tel Viking Global Investors | undisclosed |
